IntronBio's 'GNA200' Effective in Treating Carbapenem-Resistant Bacteria

[Asia Economy Reporter Hyungsoo Park] Intronbio announced on the 12th that it has confirmed the efficacy of 'GNA200,' which is being developed as a treatment for Gram-negative bacterial infections, against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates.

It is known that conventional antibiotics have reduced therapeutic effects because they do not easily penetrate the outer membrane barrier present in Gram-negative bacteria. This was also true for typical endolysin-based drugs. Intronbio developed a technology to overcome this by combining bacteriophage and endolysin technologies accumulated through long-term research with its itLysin technology. They developed the GN200 series, which can be considered the pinnacle of endolysin new drug technology.

They developed 'GNA200,' targeting Acinetobacter baumannii, which causes the most serious problems among Gram-negative bacteria. Currently, efficacy evaluation data and safety evaluation data have been secured. After establishing an industrial manufacturing process in collaboration with a global CDMO, they plan to promote early technology export.

Through efficacy evaluation, GNA200 demonstrated excellent effectiveness by killing all tested strains, including the CRAB standard strain known to be difficult to treat, as well as clinical isolates separated from patients with various diseases.

Seoyeon Jeon, head of Intronbio Biotechnology Research Center, said, "Data that can well represent the excellent characteristics of GNA200 are continuously being accumulated," adding, "These data will be usefully utilized for the planned technology export."

Kyungwon Yoon, CEO of Intronbio, said, "With company-wide efforts for rapid technology export, we expect another good achievement to be created soon," and added, "We are also continuously advancing without stopping our challenges for future innovation."

This content was produced with the assistance of AI translation services.